Psimei Pharmaceuticals PLC
Psimei Pharmaceuticals aims to improve the outcome of conventional radiotherapy for cancer patients by applying its Photon Activation Therapy (PAT) and Boron Neutron Capture Therapy (BNCT) technologies. The UK start-up has so far raised one million pounds since it was founded in January 2001.
You may also be interested in...
Imperial College spin-out Photobiotics reckons it's on track towards making photodynamic therapy (PDT) more targeted, as well as addressing some of the technique's other weaknesses.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.